Non-Hodgkin’s lymphoma (NHL) is a type of cancer of the lymphatic system, and diffuse large B-cell lymphoma (DLBCL) is a common type of NHL. DLBCL develops from abnormal B-cells (a type of white blood cell), with the abnormal cells being larger than normal, healthy B-cells. The abnormal cells in DLBCL are spread diffusely throughout the tumour. The causes of DLBCL are not known, but most people diagnosed with the disease are aged 65 years and over, and the disease affects slightly more men than women.
Lisocabtagene maraleucel (Liso-Cel) is a therapy that uses the patient’s own cells to fight the cancer. Healthy white blood cells are taken from the patient’s blood and re-programmed to fight the cancer cells in DLBCL. When these cells are returned to the body, the programmed cells act by tracking down and destroy the cancer cells. If licensed, this therapy would provide a new kind of treatment for patients whose DLBCL has come back after previous successful treatment (relapsed) or where the disease has not responded to previous treatment (refractory). This therapy also has the potential to improve patient treatment by being available in an outpatient setting when compared to similar treatments that have to be administered in a hospital/specialist setting.
Triptorelin is being developed as an injection under the skin (subcutaneous) for the treatment of locally advanced or metastatic prostate cancer. It is already marketed for this condition but is given by injection deep into the muscles (intramuscular). Triptorelin is an artificial analogue of natural gonadotropin‐releasing hormone that acts to slowly reduce the level of testosterone in the body. The first administration of triptorelin stimulates an increase in testosterone levels but prolonged administration leads to a fall in plasma testosterone or oestradiol to castrate levels which is maintained for as long as the product is administered. Triptorelin as a subcutaneous injection formulation has the potential advantage of improved safety and local tolerability when compared to intramuscular injection formulation.